CBAYCymaBay Therapeutics, Inc.

Nasdaq cymabay.com


$ 32.48 $ 0.01 (0.03 %)    

Thursday, 21-Mar-2024 15:59:50 EDT
QQQ $ 444.77 $ 0.07 (0.02 %)
DIA $ 397.57 $ 4.71 (1.2 %)
SPY $ 523.27 $ 4.36 (0.84 %)
TLT $ 94.66 $ 0.93 (0.99 %)
GLD $ 204.76 $ -0.19 (-0.09 %)
$ 32.48
$ 32.48
$ 0.00 x 0
$ 0.00 x 0
$ 32.48 - $ 32.50
$ 7.26 - $ 32.50
8,356,254
na
3.45B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-23-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-17-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-13-2021 03-31-2021 10-Q
13 03-25-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-16-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-08-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 03-15-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 05-11-2017 03-31-2017 10-Q
29 03-23-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-11-2016 03-31-2016 10-Q
33 03-29-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-11-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-23-2015 12-31-2014 10-K
38 11-14-2014 09-30-2014 10-Q
39 08-14-2014 06-30-2014 10-Q
40 05-15-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gileads-aggressive-push-beyond-hiv-treatments---plans-to-increase-cancer-focused-car-t-treatment-production

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yesc...

 top-3-health-care-stocks-that-are-ticking-portfolio-bombs

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum a...

 cymabay-announces-european-medicines-agency-accepts-for-review-the-marketing-authorization-application-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver a...

 hc-wainwright--co-reiterates-neutral-on-cymabay-therapeutics-maintains-325-price-target

HC Wainwright & Co. analyst Ed Arce reiterates CymaBay Therapeutics (NASDAQ:CBAY) with a Neutral and maintains $32.5 pri...

 cymabay-therapeutics-q4-eps-035-misses-031-estimate

CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate o...

 leerink-partners-downgrades-cymabay-therapeutics-to-market-perform-announces-325-price-target

Leerink Partners analyst Thomas Smith downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform and an...

 lifesci-capital-downgrades-cymabay-therapeutics-to-market-perform

LifeSci Capital analyst Cory Jubinville downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform.

 piper-sandler-downgrades-cymabay-therapeutics-to-neutral-lowers-price-target-to-325

Piper Sandler analyst Yasmeen Rahimi downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Overweight to Neutral and lowers the...

 cymabay-therapeutics-deal-may-not-be-needle-moving-for-100b-valued-gilead-but-acquisition-is-reasonably-priced-analyst

Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potenti...

 btig-downgrades-cymabay-therapeutics-to-neutral

BTIG analyst Julian Harrison downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Neutral.

 hc-wainwright--co-downgrades-cymabay-therapeutics-to-neutral

HC Wainwright & Co. analyst Ed Arce downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Neutral.

 cantor-fitzgerald-downgrades-cymabay-therapeutics-to-neutral-announces-325-price-target

Cantor Fitzgerald analyst Kristen Kluska downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Overweight to Neutral and announ...

 jonestrading-downgrades-cymabay-therapeutics-to-hold

JonesTrading analyst Sean Kim downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Hold.

 fear--greed-index-remains-in-extreme-greed-zone-ahead-of-inflation-data-dow-hits-record-high

The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday,...

 dow-surges-over-150-points-gilead-sciences-to-acquire-cymabay-therapeutics-for-43b

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded u...

 william-blair-downgrades-cymabay-therapeutics-to-market-perform

William Blair analyst Andy Hsieh downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform.

 cymabay-therapeutics-contextlogic-snap-and-other-big-stocks-moving-higher-on-monday

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ...

 drugmaker-gilead-sciences-scoops-up-liver-disease-focused-cymabay-therapeutics-for-43b

Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA prio...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION